Angelico Giuseppe, Santoro Angela, Inzani Frediano, Straccia Patrizia, Arciuolo Damiano, Mulè Antonino, Valente Michele, Spadola Saveria, D'Alessandris Nicoletta, Garganese Giorgia, Cianfrini Federica, Piermattei Alessia, Scambia Giovanni, Zannoni Gian Franco
Unità di Gineco-Patologia e Patologia Mammaria, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy.
Unità di Ginecologia Oncologica, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy.
Diagnostics (Basel). 2020 Dec 3;10(12):1040. doi: 10.3390/diagnostics10121040.
Extra-mammary Paget's disease (EMPD) is a rare neoplasm of epithelial origin, whose precise incidence is not clear. Starting from what is already known, we performed a systematic review and meta-analysis to investigate in male and female patients the immunohistochemical expression of biological markers that could serve as potential prognostic/therapeutic factors, including only human epidermal growth factor receptor 2 (HER2/neu), Estrogen Receptor (ER), Progesterone Receptor (PR), and Androgen Receptor (AR).
A literature search was performed of the PubMed, Scopus, and Web of Science databases for English-language studies published from January 2000 to June 2020.
A total of 27 studies with 713 patients assessed the role of HER2/neu, AR, ER, and PR expression in male and female with EMPD. The overall rate of HER2/neu expression was 30%, the expression's rate for ER and AR was 13% and 40%, respectively, and the overall rate for PR was 8%. The subgroup analysis revealed that there is a different expression of molecular markers between male and female patients.
This study revealed that AR status and HER2/neu overexpression/amplification have been shown as two fundamental pathogenetic pathways in both female and male patients affected by EMPD.
乳腺外佩吉特病(EMPD)是一种罕见的上皮源性肿瘤,其确切发病率尚不清楚。基于已知信息,我们进行了一项系统评价和荟萃分析,以研究在男性和女性患者中,可能作为潜在预后/治疗因素的生物标志物的免疫组化表达情况,这些生物标志物仅包括人表皮生长因子受体2(HER2/neu)、雌激素受体(ER)、孕激素受体(PR)和雄激素受体(AR)。
在PubMed、Scopus和Web of Science数据库中检索2000年1月至2020年6月发表的英文研究。
共有27项研究、713例患者评估了HER2/neu、AR、ER和PR表达在男性和女性EMPD患者中的作用。HER2/neu的总体表达率为30%,ER和AR的表达率分别为13%和40%,PR的总体表达率为8%。亚组分析显示,男性和女性患者之间分子标志物的表达存在差异。
本研究表明,AR状态以及HER2/neu过表达/扩增已被证明是女性和男性EMPD患者的两种基本发病机制途径。